The Editor has retracted this article [1]. Following publication significant concerns regarding the study design and analysis were raised [2]. Post-publication review confirmed a number of these aspects, including inadequate description of the trial design and that potential confounding was not sufficiently accounted for. The results and conclusions are therefore unreliable.
Gideon Koren does not agree to this retraction; Daniella Gilboa and Rachel Katz have not responded to any correspondence about this retraction.
The online version of this article contains the full text of the retracted article as electronic supplementary material.
[1] Koren, G., Gilboa, D. & Katz, R. Fetal Safety of Dydrogesterone Exposure in the First Trimester of Pregnancy. Clin Drug Investig (2019). https://doi.org/10.1007/s40261-019-00862-w
[2] Koren, G., Gilboa, D. & Katz, R. Expression of Concern to: Fetal Safety of Dydrogesterone Exposure in the First Trimester of Pregnancy. Clin Drug Investig (2020). https://doi.org/10.1007/s40261-019-00884-4
Change history
08 January 2020
The Editor-in-Chief of Clinical Drug Investigation has become aware that the original article contains a number of errors and inconsistencies.
Author information
Authors and Affiliations
Corresponding author
Additional information
The Editor has retracted this article [1]. Following publication significant concerns regarding the study design and analysis were raised [2]. Post-publication review confirmed a number of these aspects, including inadequate description of the trial design and that potential confounding was not sufficiently accounted for. The results and conclusions are therefore unreliable.
Gideon Koren does not agree to this retraction; Daniella Gilboa and Rachel Katz have not responded to any correspondence about this retraction.
The online version of this article contains the full text of the retracted article as electronic supplementary material.
[1] Koren, G., Gilboa, D. & Katz, R. Fetal Safety of Dydrogesterone Exposure in the First Trimester of Pregnancy. Clin Drug Investig (2019). https://doi.org/10.1007/s40261-019-00862-w
[2] Koren, G., Gilboa, D. & Katz, R. Expression of Concern to: Fetal Safety of Dydrogesterone Exposure in the First Trimester of Pregnancy. Clin Drug Investig (2020). https://doi.org/10.1007/s40261-019-00884-4[2] Koren, G., Gilboa, D. & Katz, R. Expression of Concern to: Fetal Safety of Dydrogesterone Exposure in the First Trimester of Pregnancy. Clin Drug Investig (2020). https://doi.org/10.1007/s40261-019-00884-4
Electronic supplementary material
Below is the link to the electronic supplementary material.
About this article
Cite this article
Koren, G., Gilboa, D. & Katz, R. RETRACTED ARTICLE: Fetal Safety of Dydrogesterone Exposure in the First Trimester of Pregnancy. Clin Drug Investig 40, 679 (2020). https://doi.org/10.1007/s40261-019-00862-w
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40261-019-00862-w